“Most cancers will be controlled through sophisticated yet widely available immune system interventions by 2050." - We at CCII will continue our research in pursuit of this universal dream for humanity.
FEATURED NEWS FROM CCII
-
NewsHighlights of CCII Opening Events
On 12th November 2024, we celebrated the Opening Ceremony for the newly constructed Bristol Myers Squibb Building, located on the Kyoto University campus, and serving as the hub for CCII's activities. Our 1st Symposium on Cancer Immunotherapy and Immunobiology followed from 13th to 15th November. Have a look at the newly published highlights!
-
NewsCCII Introduction Video Now Live!
Founded in April 2000 within Kyoto University’s Graduate School of Medicine, CCII is at the forefront of groundbreaking research in cancer immunotherapy. In this video, Kyoto University President Nagahiro Minato, CCII Director Tasuku Honjo, world-renowned architect Tadao Ando, and leading CCII researchers share insights into our center’s mission and activities.
-
ResearchPD-1 & the Immune Therapy Revolution: A 30-Year Journey
With the advent of PD-1 checkpoint inhibitors, specially designed antibodies that prevent the PD-1 protein from blocking immune cells to fight cancer, the idea of enrolling the immune system in the fight against cancer has finally become a clinical reality. However, there are still cancer patients that do not respond to PD-1 antibodies, and further research is needed to improve existing approaches.
-
ResearchRethinking the Immune Response as Metabolic Process
Immune responses are energetically expensive. Not surprisingly, secreted metabolites are increasingly emerging as important factors in immune cell maturation and activation, as this new review published in Trends in Immunology by Sidonia Fagarasan et al. demonstrates.
-
ResearchSpermidine to the Rescue?
Spermidine, a polyamine compound found in ribosomes and living tissues and originally isolated from semen, is an increasingly popular anti-aging supplement. Muna Al-Habsi and her colleagues demonstrate in a new paper published in Science that spermidine can enhance cancer immunotherapy blocking the PD-1 pathway by reversing aging effects in killer T-cells.
-
RecruitWe are permanently recruiting!
We are permanently recruiting highly motivated students, postdoctoral fellows, scientists, and technical staff. Please contact us!